Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil in High-Risk Penetrating Keratoplasty
NCT00411515Phase 4
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- University Hospital Freiburg
- Modality
- Small Molecules
- Conditions
- corneal graft rejection (CGR)
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in corneal graft rejection (CGR) (2 arms), sponsored by University Hospital Freiburg. Primary endpoints: Immune reaction free graft survival at 3 years and Clear graft survival at 3 years. Status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
MMF Group
Mycophenolate Mofetil 2g/day + Standard of Care
Control Group
Standard of Care (Systemic and Topical Steroids)
03
Endpoints
Primary
Immune reaction free graft survival
Clear graft survival
Beyond the preview
Go deeper on NCT00411515.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411515.